Published in Biochem J on January 01, 2013
Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature (2015) 2.20
Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol Cell (2014) 1.52
Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer (2015) 1.12
Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8. J Med Chem (2014) 1.05
Poised epigenetic states and acquired drug resistance in cancer. Nat Rev Cancer (2014) 1.05
Selective inhibitors of protein methyltransferases. J Med Chem (2014) 1.01
Structural analysis of the KANSL1/WDR5/KANSL2 complex reveals that WDR5 is required for efficient assembly and chromatin targeting of the NSL complex. Genes Dev (2014) 0.99
Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia. Nat Chem Biol (2015) 0.96
Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases. Q Rev Biophys (2013) 0.93
RACK1 to the future--a historical perspective. Cell Commun Signal (2013) 0.90
Open access target validation is a more efficient way to accelerate drug discovery. PLoS Biol (2015) 0.90
Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies? Immunol Rev (2015) 0.88
Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction. ACS Med Chem Lett (2013) 0.85
Open access chemical probes for epigenetic targets. Future Med Chem (2015) 0.84
An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. Nat Chem Biol (2017) 0.83
Recent developments in the use of differential scanning fluorometry in protein and small molecule discovery and characterization. Expert Opin Drug Discov (2013) 0.80
Design of a fluorescent ligand targeting the S-adenosylmethionine binding site of the histone methyltransferase MLL1. Org Biomol Chem (2015) 0.78
Inhibitors of Protein Methyltransferases and Demethylases. Chem Rev (2017) 0.76
The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochim Biophys Acta (2017) 0.76
Epigenetics: Disrupting histone lysine methylation. Nat Chem Biol (2015) 0.75
Targeting human SET1/MLL family of proteins. Protein Sci (2017) 0.75
Functional and Structural Characterization of Bub3·BubR1 Interactions Required for Spindle Assembly Checkpoint Signaling in Human Cells. J Biol Chem (2016) 0.75
CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements. Oncotarget (2016) 0.75
Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes. J Biol Chem (2016) 0.75
Development and Use of Assay Conditions Suited to Screening for and Profiling of SET-Domain-Targeted Inhibitors of the MLL/SET1 Family of Lysine Methyltransferases. Assay Drug Dev Technol (2015) 0.75
Molecular pathways: regulation and targeting of kinetochore-microtubule attachment in cancer. Clin Cancer Res (2014) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Translating the histone code. Science (2001) 56.77
MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr (2009) 53.36
HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes. Acta Crystallogr D Biol Crystallogr (2006) 13.29
WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. Cell (2005) 8.86
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell (1992) 6.11
Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct Mol Biol (2006) 6.03
The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell (1992) 5.39
PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4 methyltransferase complex. J Biol Chem (2007) 4.79
Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc Natl Acad Sci U S A (2006) 4.45
Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr Opin Cell Biol (2001) 3.86
Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive. Nature (2007) 3.68
Hox genes in hematopoiesis and leukemogenesis. Oncogene (2007) 3.55
Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes. Nat Struct Mol Biol (2006) 3.54
Chromatin remodelling factor Mll1 is essential for neurogenesis from postnatal neural stem cells. Nature (2009) 2.87
PRMT6-mediated methylation of R2 in histone H3 antagonizes H3 K4 trimethylation. Genes Dev (2007) 2.34
Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks. Mol Cell (2009) 2.32
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex. Nat Struct Mol Biol (2006) 2.29
MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell (2010) 2.29
Structural basis for molecular recognition and presentation of histone H3 by WDR5. EMBO J (2006) 2.08
p38 MAPK signaling regulates recruitment of Ash2L-containing methyltransferase complexes to specific genes during differentiation. Nat Struct Mol Biol (2007) 2.03
Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protein WDR5. Mol Cell (2006) 2.02
The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol (2011) 1.95
Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. Mol Cell (2011) 1.94
An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. Nat Biotechnol (2010) 1.88
WDR5 interacts with mixed lineage leukemia (MLL) protein via the histone H3-binding pocket. J Biol Chem (2008) 1.77
Arginine methylation of the histone H3 tail impedes effector binding. J Biol Chem (2007) 1.68
Structure of WDR5 bound to mixed lineage leukemia protein-1 peptide. J Biol Chem (2008) 1.66
Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance. Nat Struct Mol Biol (2012) 1.64
A conserved arginine-containing motif crucial for the assembly and enzymatic activity of the mixed lineage leukemia protein-1 core complex. J Biol Chem (2008) 1.61
On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex. J Biol Chem (2009) 1.61
The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood (2010) 1.60
An Ash2L/RbBP5 heterodimer stimulates the MLL1 methyltransferase activity through coordinated substrate interactions with the MLL1 SET domain. PLoS One (2010) 1.52
WDR5, a complexed protein. Nat Struct Mol Biol (2009) 1.51
Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol (2010) 1.49
Therapeutic targeting of MLL. Blood (2009) 1.36
MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines. Oncogene (1999) 1.35
Structural and biochemical insights into MLL1 core complex assembly. Structure (2011) 1.32
The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia (2010) 1.25
The plasticity of WDR5 peptide-binding cleft enables the binding of the SET1 family of histone methyltransferases. Nucleic Acids Res (2012) 1.15
Characterization of a novel WDR5-binding site that recruits RbBP5 through a conserved motif to enhance methylation of histone H3 lysine 4 by mixed lineage leukemia protein-1. J Biol Chem (2010) 1.12
Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction. J Med Chem (2010) 0.97
Fluorescence-based methods for screening writers and readers of histone methyl marks. J Biomol Screen (2011) 0.89
Fine-tuning the stimulation of MLL1 methyltransferase activity by a histone H3-based peptide mimetic. FASEB J (2010) 0.83
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature (2006) 11.86
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc (2007) 9.92
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature (2006) 7.35
Consistent blind protein structure generation from NMR chemical shift data. Proc Natl Acad Sci U S A (2008) 6.76
Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov (2012) 6.70
Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 6.52
Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J (2003) 5.78
Histone recognition and large-scale structural analysis of the human bromodomain family. Cell (2012) 5.15
PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell (2003) 5.13
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96
A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg (2010) 4.75
Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc Natl Acad Sci U S A (2006) 4.45
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43
Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell (2011) 4.41
Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis (2002) 4.23
PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet (2007) 4.09
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood (2010) 4.02
Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res (2008) 3.99
mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell (2009) 3.78
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol (2011) 3.60
Proliferative neural stem cells have high endogenous ROS levels that regulate self-renewal and neurogenesis in a PI3K/Akt-dependant manner. Cell Stem Cell (2011) 3.56
Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell (2010) 3.41
Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A (2004) 3.40
Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature (2008) 3.39
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol (2008) 3.36
Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A (2006) 3.34
A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell (2012) 3.26
Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell (2005) 3.15
In situ proteolysis for protein crystallization and structure determination. Nat Methods (2007) 3.05
A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell (2010) 3.05
Cutaneous metastases from genitourinary malignancies. Urology (2004) 2.97
PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci U S A (2005) 2.93
The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol (2009) 2.68
Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc Natl Acad Sci U S A (2005) 2.59
PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat Immunol (2004) 2.52
Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res (2009) 2.49
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell (2008) 2.48
Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature (2008) 2.47
Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. Curr Biol (2003) 2.47
Structural biology of human H3K9 methyltransferases. PLoS One (2010) 2.45
Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res (2012) 2.45
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell (2007) 2.43
Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development (2002) 2.42
Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms. Mol Biochem Parasitol (2006) 2.39
Increased expression of stem cell markers in malignant melanoma. Mod Pathol (2006) 2.39
An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. Cell (2011) 2.35
PTENless means more. Dev Biol (2004) 2.31
NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell (2006) 2.29
Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest (2007) 2.26
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res (2005) 2.22
Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell (2007) 2.14
Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J Biol Chem (2008) 2.12
L3MBTL1 recognition of mono- and dimethylated histones. Nat Struct Mol Biol (2007) 2.12
Genome-wide analysis of substrate specificities of the Escherichia coli haloacid dehalogenase-like phosphatase family. J Biol Chem (2006) 2.10
NMR data collection and analysis protocol for high-throughput protein structure determination. Proc Natl Acad Sci U S A (2005) 2.09
Structural basis for molecular recognition and presentation of histone H3 by WDR5. EMBO J (2006) 2.08
Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem (2008) 2.07
PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A (2009) 2.07
Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat Immunol (2003) 2.05
Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res (2007) 2.04
A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci (2006) 2.04
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
Hepatocellular carcinoma: stiffness value and ratio to discriminate malignant from benign focal liver lesions. Radiology (2015) 2.03
Molecular recognition of p53 and MDM2 by USP7/HAUSP. Nat Struct Mol Biol (2006) 1.97
Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. Cancer Cell (2011) 1.95
An NMR approach to structural proteomics. Proc Natl Acad Sci U S A (2002) 1.95
Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J Med Chem (2009) 1.92
Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol Cell (2005) 1.92